Associated Papers
Discovering Deleterious Single Nucleotide Polymorphisms of Human AKT1 Oncogene: An In Silico Study.
Zhang R et al.
Life (basel, Switzerland), 2023
37511907 (PubMed )
Supplement: life-13-01532-s001.zip › Supplementary_Table_S2.pdf
Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients.
Li G et al.
Plos One, 2018
30212483 (PubMed )
Supplement: pone.0203495.s006.xlsx › S4_Table
Prediction of a highly deleterious mutation E17K in AKT-1 gene: An in silico approach.
Khan I et al.
Biochemistry and Biophysics Reports, 2017
Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology.
Ibarrola-Villava M et al.
Oncotarget, 2016
26968814 (PubMed )
Supplement: oncotarget-07-22543-s001.pdf
Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer.
Xu N et al.
Oncotarget, 2016
26646697 (PubMed )
Supplement: oncotarget-07-3884-s001.pdf
Computational identification of significant missense mutations in AKT1 gene.
Shanthi V et al.
Cell Biochemistry and Biophysics, 2014
Hotspot mutations in common oncogenes are infrequent in nasopharyngeal carcinoma.
Jiang N et al.
Oncology Reports, 2014
Common oncogenic mutations are infrequent in oral squamous cell carcinoma of Asian origin.
Zanaruddin SN et al.
Plos One, 2013
24224046 (PubMed )
Supplement: pone.0080229.s001.zip › File_S1 › Table_S3-OncoCarta_Assays.xlsx › Sheet1
Fresh surgical specimens yield breast stem/progenitor cells and reveal their oncogenic abnormalities.
Pommier SJ et al.
Annals of Surgical Oncology, 2012
21748247 (PubMed )
Supplement: 10434_2011_1892_MOESM2_ESM.pdf
Select a paper to view details